(Q40960916)

25 September 2017

1 reference

title

Do monoclonal antibodies and anticytokines still have a future in infectious diseases? (English)

1 reference

25 September 2017

J Cohen

1

1 reference

25 September 2017

D Heumann

series ordinal

2

1 reference

25 September 2017

M P Glauser

series ordinal

3

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 December 1995

1 reference

American Journal of Medicine

25 September 2017

published in

1 reference

25 September 2017

volume

99

1 reference

25 September 2017

issue

6A

1 reference

25 September 2017

page(s)

45S-52S; discussion 52S-53S

1 reference

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

Antibiotic-induced release of endotoxin: a reappraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

Adjunctive therapy for septic shock: a review of experimental approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

Role of superantigens in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

The role of superantigens in human diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

Unraveling function in the TNF ligand and receptor families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

The functional role of 55- and 75-kDa tumour necrosis factor receptors in human polymorphonuclear cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

The role of interleukin-1 in disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

Interleukin 10 protects mice from lethal endotoxemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

The L-arginine-nitric oxide pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

Inhibition of nitric oxide synthase in experimental gram-negative sepsis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

Detrimental effects of a nitric oxide synthase inhibitor (N-omega-nitro-L-arginine-methyl-ester) in a murine sepsis model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980286-1

10.1016/S0002-9343(99)80286-1

7 January 2021

Identifiers

DOI

1 reference

25 September 2017

1 reference